Hence, TP-mediated prostate tumour responses not only involves PRK1, but is also dependent on signalling through the related PRK2, involving a unique and dynamic series of complexes regulated in response to agonist-activation of the TPs. Here, PKN2 is linked to prostate neoplasm.